In conclusion, accumulating studies indicate that DPP4 inhibitors are clinically useful for patients with T2DM accompanied by liver dysfunction based on fatty liver, and that DPP4 inhibition affects liver function regardless of diabetic status and obesity. This evidence concerns the gene DPP4 and Decreased liver function.